Literature DB >> 19160072

Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies.

Bharath Wootla1, Desirazu Narasimha Rao, Narasimha Rao Desirazu, Alain Friboulet, Taizo Uda, Sébastien Lacroix-Desmazes, Srini V Kaveri.   

Abstract

The versatility of antibodies is demonstrated by the various functions that they mediate such as neutralization, agglutination, fixation of the complement and its activation, and activation of effector cells. In addition to this plethora of functions, antibodies are capable of expressing enzymatic activity. Antibodies with catalytic function are a result of the productive interplay between the highly evolved machinery of the immune system and the chemical framework used to induce them (antigens). Catalytic antibodies are immunoglobulins with an ability to catalyze the reactions involving the antigen for which they are specific. Catalytic immunoglobulins of the IgM and IgG isotypes have been detected in the serum of healthy donors. In addition, catalytic immunoglobulins of the IgA isotype have been detected in the milk of healthy mothers. Conversely, antigen-specific hydrolytic antibodies have been reported in a number of inflammatory, autoimmune, and neoplastic disorders. The pathophysiological occurrence and relevance of catalytic antibodies remains a debated issue. Through the description of the hydrolysis of coagulation factor VIII as model target antigen, we propose that catalytic antibodies directed to the coagulation factor VIII may play a beneficial or a deleterious role depending on the immuno-inflammatory condition under which they occur.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19160072     DOI: 10.1007/s12016-009-8116-3

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  60 in total

1.  High levels of catalytic antibodies correlate with favorable outcome in sepsis.

Authors:  Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri; David Hayon-Sonsino; Nithyananda Thorenoor; Julien Charpentier; Charles-Edouard Luyt; Jean-Paul Mira; Valakunja Nagaraja; Michel D Kazatchkine; Jean-François Dhainaut; Vincent O Mallet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

2.  DNA hydrolyzing autoantibodies.

Authors:  A M Shuster; G V Gololobov; O A Kvashuk; A E Bogomolova; I V Smirnov; A G Gabibov
Journal:  Science       Date:  1992-05-01       Impact factor: 47.728

3.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

4.  Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation.

Authors:  Paul Wentworth; Jonathan E McDunn; Anita D Wentworth; Cindy Takeuchi; Jorge Nieva; Teresa Jones; Cristina Bautista; Julie M Ruedi; Abel Gutierrez; Kim D Janda; Bernard M Babior; Albert Eschenmoser; Richard A Lerner
Journal:  Science       Date:  2002-11-14       Impact factor: 47.728

Review 5.  Autoimmune factor VIII inhibitors.

Authors:  R K Pruthi; W L Nichols
Journal:  Curr Opin Hematol       Date:  1999-09       Impact factor: 3.284

6.  A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.

Authors:  M Shima; D Scandella; A Yoshioka; H Nakai; I Tanaka; S Kamisue; S Terada; H Fukui
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

7.  Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction.

Authors:  J G Gilles; J Arnout; J Vermylen; J M Saint-Remy
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

8.  Tissue factor antisense oligonucleotides prevent renal ischemia-reperfusion injury.

Authors:  Masahide Matsuyama; Rikio Yoshimura; Kiyokazu Akioka; Masahiko Okamoto; Hidetaka Ushigome; Yayoi Kadotani; Tatsuya Nakatani; Norio Yoshimura
Journal:  Transplantation       Date:  2003-09-15       Impact factor: 4.939

9.  A survey of 215 non-hemophilic patients with inhibitors to Factor VIII.

Authors:  D Green; K Lechner
Journal:  Thromb Haemost       Date:  1981-06-30       Impact factor: 5.249

Review 10.  Science review: role of coagulation protease cascades in sepsis.

Authors:  Matthias Riewald; Wolfram Ruf
Journal:  Crit Care       Date:  2002-10-01       Impact factor: 9.097

View more
  1 in total

1.  Deoxyribonuclease activity of polyclonal IgGs: a putative serological marker in patients with spondyloarthritides.

Authors:  Alena V Kundzer; Margarita V Volkova; Dimitrios P Bogdanos; Stefan Rödiger; Peter Schierack; I Generalov; Georgy A Nevinsky; Dirk Roggenbuck
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.